Merck Drug Price Row Loss, $56M Biotech Verdict And More
A D.C. federal court rejected Merck's challenge to the Medicare drug price negotiation program, finding its voluntary participation in federal drug programs precludes its constitutional takings claim....To view the full article, register now.
Already a subscriber? Click here to view full article